by Peter Ciszewski | Jan 25, 2022
Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, discusses the updated, long-term data from the phase 2 CAPTIVATE study. This study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic...
by Peter Ciszewski | Jan 24, 2022
David Birch, PhD, Scientific Director at the Retina Foundation of the Southwest, provides an overview of retinitis pigmentosa. As Dr. Birch explains, retinitis pigmentosa is a group of rare, inherited ophthalmological disorders that affect the retina. Retinitis...
by Peter Ciszewski | Jan 19, 2022
Jacob Laubach, MD at the Dana-Farber Cancer Institute discusses updated safety and efficacy data from the phase 2 GRIFFIN trial assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients. The data were...
by Peter Ciszewski | Jan 18, 2022
Brendan Delaney, MBA, Chief Operating Officer of Aadi Bioscience, discusses albumin-bound sirolimus (Fyarro), the recently-approved treatment for malignant perivascular epithelioid cell tumor (PEComa). PEComa is an ultra-rare family of sarcomas. Most PEComa...
by Peter Ciszewski | Jan 13, 2022
Thihan Padukkavidana, PhD, from Takeda Oncology, discusses what physicians can learn about chronic myeloid leukemia (CML) treatment based on recent data from the OPTIC trial, an ongoing open label phase 2 study testing different dosages of ponatinib for safety...
